Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05738902 | Adherence and Compliance to ERAS in Gynecological Surgery(ERASGYNBS002) | unknown | — | 600 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06223763 | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery(SUROVA) | unknown | — | 5,000 | Clinica Universidad de Navarra, Universidad de Navarra |
| 1 |
| Jan 25, 2024 |
| clinicaltrials |
| NCT06222008 | Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution | unknown | — | 40 | Yandi ZhuOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | unknown | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06182917 | Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients | unknown | — | 35 | West China Second University HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04675320 | Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors(IMMUNOPARP) | unknown | — | 50 | Centre Georges Francois LeclercOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | unknown | Phase 2 | 80 | Guangxi Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05697601 | Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools | unknown | — | 2,905 | Hasanuddin UniversityOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05048407 | Sirius in Gynaecological Laparoscopic Surgery | unknown | N/A | 30 | Precision Robotics (Hong Kong) LimitedINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05960630 | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer(MIRRORS-RCTP) | unknown | N/A | 20 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval(MITO-8) | unknown | Phase 3 | 215 | National Cancer Institute, NaplesOTHER | 3 | Nov 13, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT06120309 | New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer | unknown | — | 465 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06109545 | Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy | unknown | — | 95 | Mansoura UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06085456 | Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study | unknown | — | 1,000 | RenJi HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05272462 | Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | unknown | Phase 2 | 34 | Loyola UniversityOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT05926336 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | unknown | Phase 4 | 1,316 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT04414683 | Factors Affecting the Prognosis of Early Ovarian Cancer | unknown | — | 300 | Far Eastern Memorial HospitalOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06037213 | A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib | unknown | — | 500 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06025045 | Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments | unknown | — | 50 | Jing LiOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04768270 | The Culture of Ovarian Cancer Organoids and Drug Screening | unknown | — | 30 | Chongqing University Cancer HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05290961 | The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening | unknown | — | 30 | Chongqing University Cancer HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05805358 | Hyperpolarized 13C MRI for Cancer Immunotherapy(DNPSPIO) | unknown | Phase 2 | 90 | Chang Gung Memorial HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06010667 | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | — | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05856409 | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence | unknown | — | 20 | RenJi HospitalOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC(BEACON) | unknown | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05976932 | Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer | unknown | — | 20 | Fudan UniversityOTHER | 0 | Aug 4, 2023 | clinicaltrials |
| NCT05318625 | A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery. | unknown | N/A | 30 | Precision Robotics (Hong Kong) LimitedINDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05874115 | Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer(OutCoME) | unknown | — | 75 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05965141 | Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer | unknown | Phase 1 / Phase 2 | 38 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05223218 | Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study | unknown | — | 500 | Namida LabINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04699006 | Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. | unknown | — | 245 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05877911 | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | unknown | Phase 2 | 110 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | May 26, 2023 | clinicaltrials |
| NCT05749211 | Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer | unknown | N/A | 59 | Ruijin HospitalOTHER | 0 | May 16, 2023 | clinicaltrials |
| NCT03691012 | Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer | unknown | — | 118 | Walter and Eliza Hall Institute of Medical ResearchOTHER | 2 | May 9, 2023 | clinicaltrials |
| NCT05840029 | VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES | unknown | — | 68 | Alexandria UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05430906 | AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05824247 | A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer | unknown | — | 60 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05819060 | The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 25, 2024source: clinicaltrials